A Comprehensive Approach to MIGS.

ABiC™ is a new, comprehensive MIGS procedure that flushes out the natural outflow channels, without damaging tissue, and without leaving behind a stent or shunt. Based on the same dilation principles of traditional Canaloplasty but via a simplified and much faster surgical approach, ABiC™ is the only MIGS procedure that successfully and comprehensively addresses all aspects of potential outflow resistance. ABiC™ is also fast and easy to perform and can be successfully combined with phacoemulsification in order to make the best use of time in the operating room.

Preliminary Results

Based on preliminary results of a 228-eye case series by Mark J. Gallardo, MD (El Paso Eye Surgeons, PA) and Mahmoud A. Khaimi, MD (Dean McGee Eye Institute, OK), ABiC™ may offer better clinical outcomes than any other currently available MIGS procedure.

ABiC Effective Outside of Cataract Surgery
98 patients underwent ABiC™ as a stand-alone procedure.
Mean pre-operative IOP was 21.5 ± 7.4 mm Hg at baseline. At 12 months (n=14) mean IOP was reduced by 36.74% to 13.6 ± 1.20 mm Hg.*
The mean number of medications was 3.0 ± 1.0 at baseline. At 12 months the mean number of medications was reduced by 66.66% to 1.0. ± 1.0.*
ABiC Combined with Cataract Surgery
130 patients underwent ABiC™ in combination with phacoemulsification.
Mean preoperative IOP was 17.1 ± 5.0 mm Hg. At 12 months (n = 34) mean IOP was reduced to 13.1 ± 2.1 mm Hg.*
Mean number of medications was 2.0 ± 1.0 at baseline. At 12 months the mean number of medications was reduced by 50% to 1.0 ± 1.0.*
IOP Control in Uncontrolled Glaucoma Patients
161 uncontrolled glaucoma patients (> 16 IOP) underwent ABiC™.
Mean preoperative IOP was 21.6 ± 6.1 mm Hg at baseline. At 12 months ABiC reduced mean IOP by 38.88% to 13.2 ± 2.0 mm Hg (n=31).*
The mean number of medications was 2.0 ± 0.0 at baseline. At 12 months the mean number of medications had been reduced by 50% to 1.0 ± 1.0.*
Reducing the Medication Burden in Controlled Glaucoma Patients
ABiC was shown to effectively lower the medication burden in controlled glaucoma patients (<15 IOP) (n= 67).
Mean number of medications was 2.0 ± 1.0 at baseline. At 12 months medication-use was reduced by 50% to 1.0 ± 1.0 with IOP remaining stable in the low teens.*

The ABiC Difference

ABiC™ is the only MIGS procedure that successfully and comprehensively addresses all aspects of potential outflow resistance. Other MIGS procedures lower IOP by addressing different aspects of (rather than all aspects of) the ocular outflow system.

Physiological Outflow PathwayNon-Physiological Pathway
Collector ChannelsTrabecular MeshworkSchlemm’s CanalSubconjunctival SpaceSupraciliary space
ABiC YESYESYES
iStentYES
CyPass MicrostentYES
XEN Gel StentYES
Benefits at a Glance
1. Comprehensive: treats trabecular meshwork, Schlemm’s canal and collector channels
2. Restores natural outflow pathways with minimal tissue trauma
3. No permanent implant or stent
4. On label – patient does not have to pay additionally out of pocket
5. Patient selection criteria are similar to current MIGS procedures

The Three Simple Steps of ABiC.

STEP ONE:

After cataract surgery, perform goniotomy to open the trabecular meshwork.

ABiC-step-1-website

STEP TWO:

Prime the catheter with viscoelastic and feed it through Schlemm’S canal 360 degrees.

ABiC-step-2-website

STEP THREE:

Withdraw the catheter and viscodilate the trabecular meshwork, Schlemm’S canal and collector channels every two (2) clock hours.

ABiC-step-3-website